Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 67 of 95, showing 5 Applications out of 474 total, starting on record 331, ending on 335

# Protocol No Study Title Investigator(s) & Site(s)

331.

ECCT/22/01/03   lidERA
    A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer   
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
1. International Cancer Institute (ICI) (Uasin Gishu county)
2. Aga Khan University Hospital (Nairobi City county)
 
View

332.

ECCT/22/01/04   SKYSCRAPER 07
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE CANCERS HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY   
Principal Investigator(s)
1. Fredrick Chite Asirwa
2. Mansoor Saleh
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View

333.

ECCT/22/01/05   STEP-Mag Trial
    Simplified Treatment for Eclampsia Prevention using Magnesium sulfate:  A phase III, randomized, open label, active controlled, multicountry, multicentre, non-inferiority trial of simplified magnesium sulfate regimen for eclampsia prophylaxis (The STEP-Mag Trial)   
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
1. Nakuru Level V Hospital (Nakuru county)
2. Mama Lucy Kibaki Hospital (Nairobi City county)
3. Naivasha Level IV Hospital (Nakuru county)
 
View

334.

ECCT/22/01/06   AIKILI Technology
    Feasibility and accuracy of nanosensor-based breast cancer diagnosis at the point-of-care-AIKILI technology       
Principal Investigator(s)
1. Laura Kelley Kelley
Site(s) in Kenya
Aga Khan University Hospital, Nairobi.
 
View

335.

ECCT/22/02/01   An Open label Inclacumab study
    An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Fredrick Asirwa Chite
3. Videlis N nduba
4. Prof Jessie N Githanga
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
5. Gertrude’s Children’s Hospital. (Nairobi City county)
6. Strathmore University Medical Centre (Nairobi City county)
 
View